"Aged" fibroblasts, prevention of aging (H2O2 stimulation)| Type of assay | beta-galactosidase | | Biological model | Dermal fibroblasts, accelerated aging model (H2O2 induced) | | Species | Human | | Endpoint | beta-galactosidase activity |
| NHDFA2-0003 | Intrinsic aging (dermis) | beta-galactosidase | Dermal fibroblasts, accelerated aging model (H2O2 induced) | Human | beta-galactosidase activity | Flow cytometry | Basal | |
3D sebocytes, Ki67 expression (proliferation marker) (basal)| Type of assay | Proliferation | | Biological model | SEBO662 3D model, BIOalternatives | | Species | Human | | Endpoint | Ki67 immunolabeling & tissu thickness |
| SEBO3D-0004 | Acne, Acne, Sebaceous glands, Oily skin, Dry skin | Proliferation | SEBO662 3D model, BIOalternatives | Human | Ki67 immunolabeling & tissu thickness | Immunohistofluorescence | Basal | |
3D sebocytes, lipid accumulation (basal)| Type of assay | Lipid accumulation | | Biological model | SEBO662 3D model, BIOalternatives | | Species | Human | | Endpoint | Lipid labeling |
| SEBO3D-0005 | Acne, Acne, Sebaceous glands, Oily skin, Dry skin | Lipid accumulation | SEBO662 3D model, BIOalternatives | Human | Lipid labeling | Histology (Oil Red O Staining) | Basal | |
3D sebocytes, sebocyte differentiation markers (basal)| Type of assay | Protein markers | | Biological model | SEBO662 3D model, BIOalternatives | | Species | Human | | Endpoint | Epithelial membrane antigen (EMA) & cytokeratin 7 immunolabeling |
| SEBO3D-0002 | Acne, Acne, Sebaceous glands, Oily skin, Dry skin | Protein markers | SEBO662 3D model, BIOalternatives | Human | Epithelial membrane antigen (EMA) & cytokeratin 7 immunolabeling | Immunohistofluorescence | Basal | |
3D sebocytes, sebocyte differentiation markers (basal)| Type of assay | Gene expression | | Biological model | SEBO662 3D model, BIOalternatives | | Species | Human | | Endpoint | mRNA EMA/MUC1, KRT7, PPARG |
| SEBO3D-0003 | Acne, Acne, Sebaceous glands, Oily skin, Dry skin | Gene expression | SEBO662 3D model, BIOalternatives | Human | mRNA EMA/MUC1, KRT7, PPARG | RT-qPCR | Basal | |
3D sebocytes, testosterone metabolism & 5- alpha reductase activity (basal)| Type of assay | Androgen metabolism | | Biological model | SEBO662 3D model, BIOalternatives | | Species | Human | | Endpoint | 5- alpha reductase activity |
| SEBO3D-0001 | Acne, Acne, Sebaceous glands, Oily skin | Androgen metabolism | SEBO662 3D model, BIOalternatives | Human | 5- alpha reductase activity | [14C]-testosterone incorporation | Basal | |
Astrocytes, chemokine production (cytokine stimulation)| Type of assay | Cytokines/chemokines | | Biological model | Astrocytes | | Species | Mouse | | Endpoint | CCL5 release |
| ASTRO-0001 | CNS inflammation | Cytokines/chemokines | Astrocytes | Mouse | CCL5 release | ELISA / EIA | IL-1 beta / IL-6 / TNF- alpha | |
Blood, human basophil activation assay (BAT)| Type of assay | Degranulation | | Biological model | Whole Blood | | Species | Human | | Endpoint | CD63 expression |
| BLOO-0008 | Immuno-inflammation assays using blood/immune cells | Degranulation | Whole Blood | Human | CD63 expression | Flow cytometry | Basal | |
Caspase 1, enzymatic activity| Type of assay | Enzyme activity | | Biological model | | | Species | Human | | Endpoint | Caspase-1 activity |
| BIOCH-0034 | Enzyme activity assays, Wound healing, trauma & agressions, Wound healing, trauma & aggressions | Enzyme activity | | Human | Caspase-1 activity | Fluorescence | | |
HUVEC, differentiation (basal)| Type of assay | Differentiation | | Biological model | Umbilical vein endothelial cells (HUVEC) | | Species | Human | | Endpoint | Pseudotube formation |
| HUVEC-0008 | Vascularization, Wound healing, trauma & agressions, Wound healing, trauma & aggressions | Differentiation | Umbilical vein endothelial cells (HUVEC) | Human | Pseudotube formation | Imaging | Basal | |
Hippocampal neurons, chemokine production (cytokine mix stimulation)| Type of assay | Cytokines/chemokines | | Biological model | Hippocampal neurons | | Species | Mouse | | Endpoint | CCL5 release |
| NHIPP-0005 | CNS inflammation | Cytokines/chemokines | Hippocampal neurons | Mouse | CCL5 release | ELISA / EIA | Cytokines mix (TNF- alpha, IL-1 beta, IL-6) | |
Mo-LC, cytokine release (PGN stimulation)| Type of assay | Cytokines/chemokines | | Biological model | Monocyte-derived Langerhans cells (CD34+ LC) | | Species | Human | | Endpoint | IL-8 release |
| MOLC-0002 | Dendritic & Langerhans cells, Dendritic & Langerhans cells: inflammation, innate & adaptative immunity | Cytokines/chemokines | Monocyte-derived Langerhans cells (CD34+ LC) | Human | IL-8 release | ELISA / EIA | PGN | |
NHDF, MMP1 gene expression (IR stimulation)| Type of assay | ECM synthesis/degradation | | Biological model | Dermal fibroblasts (NHDF) | | Species | Human | | Endpoint | mRNA MMP1 |
| NHDF-0084 | Photo-aging (dermis), Photo-aging, UV, solar (dermis) | ECM synthesis/degradation | Dermal fibroblasts (NHDF) | Human | mRNA MMP1 | RT-qPCR | IR | |
NHDF, cAMP content (basal)| Type of assay | Signal transduction | | Biological model | Dermal fibroblasts (NHDF) | | Species | Human | | Endpoint | cAMP content |
| NHDF-0081 | Fibroblast viability & metabolism | Signal transduction | Dermal fibroblasts (NHDF) | Human | cAMP content | HTRF | Basal | |
NHDF, calcium mobilization (Bradykinin stimulation )| Type of assay | Signal transduction | | Biological model | Dermal fibroblasts (NHDF) | | Species | Human | | Endpoint | Calcium mobilization |
| NHDF-0083 | Fibroblast viability & metabolism | Signal transduction | Dermal fibroblasts (NHDF) | Human | Calcium mobilization | Time-lapse microscopy | Bradykinin | |
NHDF, calcium mobilization (basal)| Type of assay | Signal transduction | | Biological model | Dermal fibroblasts (NHDF) | | Species | Human | | Endpoint | Calcium mobilization |
| NHDF-0082 | Fibroblast viability & metabolism | Signal transduction | Dermal fibroblasts (NHDF) | Human | Calcium mobilization | Time-lapse microscopy | Basal | |
NHDF, protein neosynthesis (basal)| Type of assay | Metabolism | | Biological model | Dermal fibroblasts (NHDF) | | Species | Human | | Endpoint | Protein neosynthesis |
| NHDF-0080 | Fibroblast viability & metabolism | Metabolism | Dermal fibroblasts (NHDF) | Human | Protein neosynthesis | [3H]-leucine incorporation | Basal | |
NHEK + NHEM, inhibition of melanin synthesis (Basal, depigmenting molecules)| Type of assay | Melanin synthesis | | Biological model | Keratinocytes + Melanocytes, coculture | | Species | Human | | Endpoint | Melanin content |
| KM-0015 | Melanogenesis, Pigmentation disorders | Melanin synthesis | Keratinocytes + Melanocytes, coculture | Human | Melanin content | Photometry | Basal | |
NHEK + NHEM, melanocyte dendricity (IBMX stimulation)| Type of assay | Melanocyte dendricity | | Biological model | Keratinocytes + Melanocytes, coculture | | Species | Human | | Endpoint | Dendrite network |
| KM-0016 | Melanin transfer, Pigmentation disorders | Melanocyte dendricity | Keratinocytes + Melanocytes, coculture | Human | Dendrite network | Immunofluorescence | IBMX | |
NHEK, calcium mobilization (basal)| Type of assay | Signal transduction | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | Calcium mobilization |
| NHEK-0141 | Keratinocyte inflammatory response to small bioactive molecules, Keratinocyte response to small bioactive molecules | Signal transduction | Epidermal keratinocytes (NHEK) | Human | Calcium mobilization | Time-lapse microscopy | Basal | |
NHEK, protein neosynthesis (basal)| Type of assay | Metabolism | | Biological model | Epidermal keratinocytes (NHEK) | | Species | Human | | Endpoint | Protein neosynthesis |
| NHEK-0140 | Keratinocyte viability & metabolism | Metabolism | Epidermal keratinocytes (NHEK) | Human | Protein neosynthesis | [3H]-leucine incorporation | Basal | |
Sebocytes, proliferation (basal)| Type of assay | | | Biological model | SEBO662 sebocyte cell line, BIOalternatives | | Species | Human | | Endpoint | Proliferation |
| SEBO-0001 | Acne, Sebaceous glands, Oily skin, Dry skin | | SEBO662 sebocyte cell line, BIOalternatives | Human | Proliferation | BrdU incorporation + MTT reduction assay (image capture) | Basal | |
Sebocytes, testosterone metabolism & 5- alpha reductase activity (basal)| Type of assay | Androgen metabolism | | Biological model | SEBO662 sebocyte cell line, BIOalternatives | | Species | Human | | Endpoint | 5- alpha reductase activity |
| SEBO-0003 | Acne, Acne, Sebaceous glands, Oily skin | Androgen metabolism | SEBO662 sebocyte cell line, BIOalternatives | Human | 5- alpha reductase activity | [14C]-testosterone incorporation | Basal | |
Sensory neurons, substance P release (Basal)| Type of assay | Neuromediators | | Biological model | Sensory neurons | | Species | Rat | | Endpoint | Substance P release |
| NS-0011 | Sensitive skin, Pruritus, itching, Pruritus, itching, Peripheral inflammation, sensitivity, pain, itching | Neuromediators | Sensory neurons | Rat | Substance P release | ELISA / EIA | Basal | |
Skin maintained ex vivo, ECM constituents (Alcian blue staining) (basal)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Mucine/GAG staining |
| SKIN-0042 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Mucine/GAG staining | Histology (Alcian blue staining) | Basal | |
Skin maintained ex vivo, ECM constituents (Luna staining)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Elastic fiber staining |
| SKIN-0038 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Elastic fiber staining | Histology (Luna staining) | Basal | |
Skin maintained ex vivo, ECM constituents (Movat's Pentachrome staining)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Elastic and collagen fiber staining |
| SKIN-0039 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Elastic and collagen fiber staining | Histology (Movat's Pentachrome staining) | Basal | |
Skin maintained ex vivo, ECM constituents (Orcein staining)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Elastic fiber staining |
| SKIN-0040 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Elastic fiber staining | Histology (Orcein staining) | Basal | |
Skin maintained ex vivo, ECM constituents (PAS staining)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Glycogen, collagen staining |
| SKIN-0036 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Glycogen, collagen staining | Histology (PAS staining) | Basal | |
Skin maintained ex vivo, ECM constituents (Sirius Red staining)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Collagen staining |
| SKIN-0037 | ECM synthesis, Skin morphology | Histology | Skin (ex vivo) | Human | Collagen staining | Histology (Sirius Red staining) | Basal | |
Skin maintained ex vivo, in situ tyrosinase activity (basal)| Type of assay | Melanogenic proteins | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Tyrosinase activity |
| SKIN-0024 | Melanogenesis, Pigmentation disorders | Melanogenic proteins | Skin (ex vivo) | Human | Tyrosinase activity | | Basal | |
Skin maintained ex vivo, morphology (Oil Red O staining) (basal)| Type of assay | Histology | | Biological model | Skin (ex vivo) | | Species | Human | | Endpoint | Lipid staining |
| SKIN-0041 | Sebaceous glands, Skin morphology | Histology | Skin (ex vivo) | Human | Lipid staining | Histology (Oil Red O Staining) | Basal | |
T cells, cytokine release (anti-CD3/anti-CD28 stimulation)| Type of assay | Th2 polarity - Cytokines | | Biological model | PBMCs | | Species | Human | | Endpoint | TNF- alpha release, or other Th2 cytokines, IL-4 release, IL-13 release, IL-31 release |
| PBMC-0009 | T lymphocytes: anti-inflammatory effects/immunosuppression, Atopic dermatitis, Atopic dermatitis, T lymphocytes: anti-inflammatory effects/immunosuppression - cell-mediated and humoral immunity modulation | Th2 polarity - Cytokines | PBMCs | Human | TNF- alpha release, or other Th2 cytokines, IL-4 release, IL-13 release, IL-31 release | ELISA / EIA | Anti-CD28 / Anti-CD3 | |
THP-1, IL-1 beta release (LPS stimulation)| Type of assay | Inflammatory cytokines | | Biological model | THP-1 cell line | | Species | Human | | Endpoint | IL-1 beta release |
| THP1-0004 | Monocytes/macrophages, Monocytes/macrophages: inflammation, innate immunity | Inflammatory cytokines | THP-1 cell line | Human | IL-1 beta release | ELISA / EIA | LPS | |
THP1, caspase 1, enzymatic activity (basal)| Type of assay | Enzyme activity | | Biological model | THP-1 cell line | | Species | Human | | Endpoint | Caspase-1 activity |
| THP1-0006 | Monocytes/macrophages, Monocytes/macrophages: inflammation, innate immunity | Enzyme activity | THP-1 cell line | Human | Caspase-1 activity | Fluorescence | Basal | |
